NASDAQ:TNYA Tenaya Therapeutics Q4 2023 Earnings Report $1.41 +0.09 (+6.82%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.40 -0.01 (-1.06%) As of 09/19/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Tenaya Therapeutics EPS ResultsActual EPS-$0.40Consensus EPS -$0.45Beat/MissBeat by +$0.05One Year Ago EPSN/ATenaya Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATenaya Therapeutics Announcement DetailsQuarterQ4 2023Date3/18/2024TimeN/AConference Call DateMonday, March 18, 2024Conference Call Time4:00PM ETUpcoming EarningsTenaya Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tenaya Therapeutics Earnings HeadlinesTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)September 18 at 4:05 PM | globenewswire.comTenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 20 at 2:00 AM | Porter & Company (Ad)Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 2, 2025 | globenewswire.comTenaya Therapeutics Reports Interim Data from Largest Pediatric MYBPC3-Associated HCM Study Highlighting Urgent Need for Novel TherapeuticsAugust 31, 2025 | quiverquant.comQTenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025August 31, 2025 | globenewswire.comSee More Tenaya Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenaya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenaya Therapeutics and other key companies, straight to your email. Email Address About Tenaya TherapeuticsTenaya Therapeutics (NASDAQ:TNYA) is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses. Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease. The company’s lead programs are advancing through preclinical and early clinical stages, with a focus on establishing proof of concept in relevant patient populations. Research collaborations and strategic partnerships support Tenaya’s efforts to accelerate development timelines and expand its scientific capabilities. Tenaya operates primarily in the United States, where it maintains its main research and manufacturing facilities. The company also engages with regulatory authorities to shape the clinical development and eventual commercialization of its therapies. Its management team combines expertise in gene therapy, cardiovascular biology and biopharmaceutical development, positioning Tenaya to tackle the complex challenges of translating novel genetic medicines into practical treatments. With a commitment to addressing unmet needs in cardiovascular health, Tenaya Therapeutics seeks to transform the treatment landscape for patients with inherited heart diseases. By integrating advanced vector engineering with a deep understanding of cardiac biology, the company strives to deliver breakthrough therapies that offer long‐lasting benefits and improved quality of life.View Tenaya Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Berkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into Believers Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
